Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. - Wikidata - wikimedia - TriplyDB

Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations.

Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations.

http://www.wikidata.org/entity/Q37453883

about

Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment Interleukin 17 in vascular inflammation.Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension.Increased levels of asymmetric dimethylarginine are associated with pulmonary arterial hypertension in HIV infection.Serum amyloid A is a marker for pulmonary involvement in systemic sclerosis.Reduced B lymphoid kinase (Blk) expression enhances proinflammatory cytokine production and induces nephrosis in C57BL/6-lpr/lpr mice.Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.Osteopontin in systemic sclerosis and its role in dermal fibrosis Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles.STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation.CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts.Cytokine profiles in localized scleroderma and relationship to clinical features.Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis.Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.Cartilage oligomeric matrix protein-induced complement activation in systemic sclerosis Biomarkers for skin involvement and fibrotic activity in scleroderma.Immunotherapeutic implication of IL-6 blockade.Circulating biomarkers of interstitial lung disease in systemic sclerosis.Increased expression of endoplasmic reticulum stress and unfolded protein response genes in peripheral blood mononuclear cells from patients with limited cutaneous systemic sclerosis and pulmonary arterial hypertension.Facts and promises on lung biomarkers in interstitial lung diseases.The role of the acquired immune response in systemic sclerosis.T and NK Cell Phenotypic Abnormalities in Systemic Sclerosis: a Cohort Study and a Comprehensive Literature Review.Novel investigational therapies for treating pulmonary arterial hypertension.IL-17, IL-6 and IFN-γ in Systemic Sclerosis Patients.The role of inflammatory biomarkers in CHD-associated pulmonary hypertension in children.Potential roles of interleukin-17A in the development of skin fibrosis in mice.Targeting STAT4 in systemic sclerosis: a promising new direction.Supernatants from culture of type I collagen-stimulated PBMC from patients with cutaneous systemic sclerosis versus localized scleroderma demonstrate suppression of MMP-1 by fibroblasts.Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension.Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study.Increased expression of S100A8 and S100A9 in patients with diffuse cutaneous systemic sclerosis. A correlation with organ involvement and immunological abnormalities.Cell surface expression of activating receptors and co-receptors on peripheral blood NK cells in systemic autoimmune diseases.Biomarkers in connective tissue diseases.Increased frequencies of circulating CXCL10-, CXCL8- and CCL4-producing monocytes and Siglec-3-expressing myeloid dendritic cells in systemic sclerosis patients.IL-17 and related cytokines involved in systemic sclerosis: Perspectives.Pulmonary hypertension in systemic lupus erythematosus: echocardiography-based definitions predict 6-year survival.Interferons and systemic sclerosis: correlation between interferon gamma and interferon-lambda 1 (IL-29).

P2860

Q26995542-8BBEE533-E10B-4DE0-9800-E4D635314CBC Q30429445-A77112F4-D717-48F7-9A24-AB40B09D9C19 Q33649222-5CE47397-9CB7-46B4-85E2-418A4B283EFE Q34109306-32895FBF-9C8C-4799-AE1A-EA01D8468491 Q35064030-1C658ADE-0F2E-4E1E-9250-21B895656CD1 Q35122990-38B6D2BF-2DB2-4993-8347-85B8A61C1763 Q35724900-03DA807F-C8B1-4C3A-974F-247C1431B16B Q36002290-DF0AECE8-382B-4998-A4F8-BF8B5D2AABD7 Q36185917-AC61D750-8F21-44DE-A536-C08BA0090E51 Q36307704-159A1C4D-95E9-4FF4-AA89-4BD2C326651D Q36385387-470147B5-0AA4-41DF-BD9F-ECD9C996F04D Q36391220-B925B90A-FA04-4A78-89D3-ED488DE26505 Q36784652-78B90E2D-6F7A-4350-B777-8AC9F4CC6BDB Q36871425-789A4F4D-B008-4D30-B583-3FD313B72370 Q36942366-893E882C-C031-4D6D-B9A6-406970AAE758 Q37276787-51C50CB0-7C22-4F78-8DF6-88DEECEFA14C Q37547111-F80C6C44-FA2B-437C-8294-B5B7ADD79A92 Q37690254-60B144DB-F947-4952-9032-887F81A69B43 Q37912251-F2A5B53B-EF7F-4659-B402-8D4E8A12F731 Q37965754-5D2A6C86-A009-49D6-8DB0-444880050134 Q38044387-0028783C-C5A4-4CE5-8B11-F07D05578F93 Q38317794-C9708153-1A44-40DC-8AAC-8EE5E913B694 Q38543042-F7824A09-9337-410F-9477-F6F5D1AA3D70 Q38543690-3DFF5C63-147B-4654-A11C-EEADF3A82195 Q38601631-65EA855F-70EB-4B72-B643-C4972A995A30 Q38612061-D85C5762-9917-445E-B270-E4270FE329C2 Q38995396-16C6CF99-7BB9-4049-BCB8-951CD56AF06D Q39213635-3FD52A94-8254-4B6D-9D30-363B21079AFC Q39308063-C3C2DA67-3140-4BBC-9B49-054F3CA111F6 Q39724674-9CC15A83-C923-4F90-80B0-2A151E95AED5 Q42180802-76A10476-E5AC-43E7-B503-D426FA4FCF46 Q42407453-2EA2BB37-BBAE-45B1-803B-7161E60C1CBE Q44131640-A4DE2695-00DE-44CF-8FF1-BB9ADDB2F6FD Q44751936-D6FD2832-C993-4136-B0F6-8AACD4C72EFC Q46093248-182DE322-A754-496C-88AA-1ED82F01652D Q47314399-8CE13686-FD5D-4A2C-8EC9-C81F81E885B1 Q47614995-FC7D33C6-9E11-48C5-8BA7-D52985428B06 Q47774368-23C0A5E5-C618-4230-8AA0-F5F4F27C6197 Q53094081-0A2ACD6A-87DF-49A9-8365-879F914DA5BF Q53474166-40E41346-A882-4315-BFB3-F869D362DD47

P2860

Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations.

http://www.wikidata.org/entity/Q37453883

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 October 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Plasma cytokine profiles in sy ...... s and clinical manifestations.

@en

Plasma cytokine profiles in sy ...... s and clinical manifestations.

@nl

type

label

Plasma cytokine profiles in sy ...... s and clinical manifestations.

@en

Plasma cytokine profiles in sy ...... s and clinical manifestations.

@nl

prefLabel

Plasma cytokine profiles in sy ...... s and clinical manifestations.

@en

Plasma cytokine profiles in sy ...... s and clinical manifestations.

@nl

P1433

Q37453883-12B060CA-856E-4FC3-87F6-5638F5A8297C

P1476

Q37453883-C12D2CEF-C3B4-4D67-A2D9-3E4D3C366328

P2093

Q37453883-042469E4-85B8-4D3E-BA4F-025A694205F6

Q37453883-6B96E505-6AB4-4381-BD43-5A7CA8C5CC22

Q37453883-6DA38D43-D38D-4AD8-AB5C-BEB601455ED1

Q37453883-A5D82E16-B875-4232-AD86-E8FBD3D5AC7A

Q37453883-BBE0F667-A875-45D1-B8EC-45D541B91B52

Q37453883-C3EF2FD0-00DF-497C-8AE4-9C34D92482CB

Q37453883-E0084091-A5F9-4721-BE70-BD6D3CF25689

Q37453883-FADC2517-787E-43E3-9F49-F096AEBE1300

P2860

Q37453883-1130DAA8-7A83-4B67-9DB3-EAC44362BCF4

Q37453883-28D26CE9-499B-4933-9763-EB11CA0034FC

Q37453883-592541DB-9A97-44E3-9401-7B6740173976

Q37453883-66D0A27A-7D4D-4CC5-B63E-85817BE46F1B

Q37453883-77BFE0A0-9D1C-4768-BB7F-D6CF90EF86E6

Q37453883-7E682C8C-E814-4C0A-98A8-8C7B770F334F

Q37453883-88079258-FBC5-4EE1-913B-5BCA6F82D31D

Q37453883-888FB72B-388F-45DE-815A-5DF861D648E7

Q37453883-8D785558-2668-436D-9AB4-A40A091E616A

Q37453883-A6B43793-7BDF-4FB0-A03D-9BDC5606BC85

P2888

Q37453883-F1C904E1-8BA0-46CC-B19E-4CFD39777400

P304

Q37453883-572CCBA9-A7EA-4E2E-A109-B6085679E17F

P31

Q37453883-232491D7-0D00-4A26-9434-1EA26441C862

P356

Q37453883-94A90506-3351-4E25-9744-F1AE6E06AF6F

P433

Q37453883-8D6CB22A-0891-43EF-A7B5-1024133CFCA8

P478

Q37453883-20B353D8-66A6-4629-BC5C-34D0D9632C60

P50

Q37453883-9EEEF3CE-8737-419A-AFC0-2EEABA78F200

P577

Q37453883-69C12477-F4F4-44FF-9C43-1C768A8E5472

P5875

Q37453883-0835F995-F46C-4754-95D1-815A16B8DC2C

P6179

Q37453883-88A99308-A5CC-434D-9D09-D5E00DB952A2

P698

Q37453883-7951F329-B22D-4B11-9D49-DFF89D1DB6C0

P921

Q37453883-DB9F3E59-AE8F-474B-A8EF-D35B8B492BC3

P932

Q37453883-8E8D6C48-EEBA-46DC-860E-F783297F09F9

P356

P1433

Arthritis Research and Therapy

P1476

Plasma cytokine profiles in sy ...... s and clinical manifestations.

@en

P2093

Filemon K Tan

http://www.w3.org/2001/XMLSchema#string

Frank C Arnett

http://www.w3.org/2001/XMLSchema#string

Laura Diekman

http://www.w3.org/2001/XMLSchema#string

Maureen D Mayes

http://www.w3.org/2001/XMLSchema#string

Mei Huang

http://www.w3.org/2001/XMLSchema#string

Pravitt Gourh

http://www.w3.org/2001/XMLSchema#string

Sandeep K Agarwal

http://www.w3.org/2001/XMLSchema#string

Shervin Assassi

http://www.w3.org/2001/XMLSchema#string

P2860

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

The paradigm of IL-6: from basic science to medicine

Role of profibrogenic cytokines secreted by T cells in fibrotic processes in scleroderma.

The assessment of the patient with systemic sclerosis. Introduction.

Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis.

Th17: the third member of the effector T cell trilogy.

Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee

Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants.

Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation.

P2888

P304

R147

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/AR2821

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

John D Reveille

P577

2009-10-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26866108

http://www.w3.org/2001/XMLSchema#string

P6179

1047939160

http://www.w3.org/2001/XMLSchema#string

P698

19799786

http://www.w3.org/2001/XMLSchema#string

P921

P932

2787259

http://www.w3.org/2001/XMLSchema#string